Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma : A Randomized Phase 2 Study - Lindskog, M. (Department of Immunology. Genetics and Pathology. Uppsala University Hospital. Uppsala University) ; Laurell, Anna (Department of Oncology. Akademiska University Hospital) ; Kjellman, Anders (Department of Urology. CLINTEC. Karolinska University Hospital. Karolinska Institutet) ; Melichar, Bohuslav (Department of Urology and Urological Oncology. Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Zieliński, Henryk (Clinical Urology. Military Institute of Medicine) ; Villacampa, Felipe (Hospital Universitario 12 de Octubre (Madrid). Servicio de Urología) ; Bigot, Pierre (Department of Urology. Centre Hospitalier Universitaire d'Angers) ; Zoltan, Bajory (Szent-Györgyi Albert Klinikai Központ. Szegedi Tudomanyegyetem Altalanos Ovostudomanyi Kar Urologiai Klinika) ; Parikh, Omi (Rosemere Cancer Centre. Royal Preston Hospital) ; Vázquez Alba, David (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Jellvert, Åsa (Department of Oncology. Institute of Clinical Sciences. Sahlgrenska Academy. University of Gothenburg) ; Flaskó, Tibor (Department of Urology. Medical School. University of Debrecen) ; Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Ribal Caparrós, María José (Hospital Clínic i Provincial de Barcelona) ; Purkalne, Gunta (Oncology Clinic. Pauls Stradins Clinical University Hospital) ; Suenaert, Peter (Immunicum AB) ; Karlsson-Parra, Alex (Department of Immunology. Genetics and Pathology. Section of Clinical Immunology. Uppsala University) ; Ljungberg, Börje (Department of Surgical and Perioperative Sciences. Urology and Andrology. Umeå University) ; Universitat Autònoma de Barcelona